A second priority area is the issue of intellectual property rights. Those investing in research need the opportunity to recover their investment. And, producer access to the new technology should be done in a manner that does not unduly affect their operations. A third area is trade. International acceptance and movement must be assured as approved biotech products become more common.
Science is science.
When the scientific community approves a product, that should be the end of the discussion. A product should be able to move through trade channels without facing pseudo-scientific barriers or charges of imaginary health dangers. Due to earlier international trade negotiations, appropriate mechanisms are in place to address such disputes. The World Trade Organization will play a large role as mediator in future conflicts. The fourth and most critical area is consumer education.